Pregnancy outcome and influencing factors of patients with adenomyosis after FUAS treatment

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300072178

Enrollment

Unknown

Registered

2023-06-06

Start date

2023-06-06

Completion date

Unknown

Last updated

2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenomyosis

Interventions

Endometrial tissue before and after Fuas treatment:N/A

Eligibility

Sex/Gender

Female

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) Adenomyosis was definitely diagnosed by MRI; (2) Patients with previous vaginal delivery; (3) Female aged 20-45; (4) Non-menstrual period and normal leucorrhea; (5) Voluntarily agree to participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Pregnancy and lactation; (2) Severe heart, lung, liver and kidney diseases cannot tolerate anesthesia; (3) Acute pelvic inflammatory disease, endometritis and vaginitis; (4) Severe coagulation dysfunction;

Design outcomes

Primary

Measure	Time frame
Expression of immune cells UNK (CD57) ; Expression of macrophages (CD68) ; Expression of endometrial ESR1 ; Expression of macrophages (CD68) ; Expression of endometrial ESR1;	—

Countries

china

Contacts

Public ContactZhang lian

Chongqing Haifu Hospital

lianwzhang@yahoo.com+86 136 3789 3738

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026